Apyx Medical Corporation

NasdaqGS:APYX Stock Report

Market Cap: US$43.7m

Apyx Medical Management

Management criteria checks 3/4

Apyx Medical's CEO is Charlie Goodwin, appointed in Dec 2017, has a tenure of 6.33 years. total yearly compensation is $1.26M, comprised of 38.2% salary and 61.8% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth $113.40K. The average tenure of the management team and the board of directors is 5.8 years and 6.8 years respectively.

Key information

Charlie Goodwin

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage38.2%
CEO tenure6.3yrs
CEO ownership0.3%
Management average tenure5.8yrs
Board average tenure6.8yrs

Recent management updates

Recent updates

Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive

Apr 18
Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive

Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates

Mar 26
Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates

Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)

Feb 16
Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)

Is Apyx Medical (NASDAQ:APYX) A Risky Investment?

Sep 14
Is Apyx Medical (NASDAQ:APYX) A Risky Investment?

Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?

Jun 07
Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?

Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically

Mar 21
Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically

Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation

Dec 14
Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation

We're Not Very Worried About Apyx Medical's (NASDAQ:APYX) Cash Burn Rate

Aug 30
We're Not Very Worried About Apyx Medical's (NASDAQ:APYX) Cash Burn Rate

Apyx Medical GAAP EPS of -$0.16 beats by $0.03, revenue of $10.3M misses by $0.26M

Aug 11

Apyx Medical gets FDA nod for Renuvion's use in improving loose skin on neck, chin

Jul 18

Companies Like Apyx Medical (NASDAQ:APYX) Are In A Position To Invest In Growth

May 26
Companies Like Apyx Medical (NASDAQ:APYX) Are In A Position To Invest In Growth

Are Investors Undervaluing Apyx Medical Corporation (NASDAQ:APYX) By 42%?

Mar 15
Are Investors Undervaluing Apyx Medical Corporation (NASDAQ:APYX) By 42%?

We Think Apyx Medical (NASDAQ:APYX) Can Easily Afford To Drive Business Growth

Jan 08
We Think Apyx Medical (NASDAQ:APYX) Can Easily Afford To Drive Business Growth

We Think Apyx Medical (NASDAQ:APYX) Can Easily Afford To Drive Business Growth

Sep 28
We Think Apyx Medical (NASDAQ:APYX) Can Easily Afford To Drive Business Growth

Most Shareholders Will Probably Find That The CEO Compensation For Apyx Medical Corporation (NASDAQ:APYX) Is Reasonable

Jul 31
Most Shareholders Will Probably Find That The CEO Compensation For Apyx Medical Corporation (NASDAQ:APYX) Is Reasonable

CEO Compensation Analysis

How has Charlie Goodwin's remuneration changed compared to Apyx Medical's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$1mUS$483k

-US$19m

Sep 30 2023n/an/a

-US$15m

Jun 30 2023n/an/a

-US$16m

Mar 31 2023n/an/a

-US$21m

Dec 31 2022US$2mUS$483k

-US$23m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$18m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$2mUS$450k

-US$15m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$14m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$2mUS$450k

-US$12m

Sep 30 2020n/an/a

-US$16m

Jun 30 2020n/an/a

-US$16m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$2mUS$450k

-US$20m

Sep 30 2019n/an/a

-US$18m

Jun 30 2019n/an/a

-US$15m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$1mUS$400k

-US$11m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$12m

Mar 31 2018n/an/a

-US$15m

Dec 31 2017US$2mUS$15k

-US$14m

Compensation vs Market: Charlie's total compensation ($USD1.26M) is above average for companies of similar size in the US market ($USD677.87K).

Compensation vs Earnings: Charlie's compensation has been consistent with company performance over the past year.


CEO

Charlie Goodwin (56 yo)

6.3yrs

Tenure

US$1,261,470

Compensation

Mr. Charles D. Goodwin II, also known as Charlie, has been Chief Executive Officer and Director of Apyx Medical Corporation (formerly known as Bovie Medical Corporation) since December 15, 2017 and serves...


Leadership Team

NamePositionTenureCompensationOwnership
Charles Goodwin
President6.3yrsUS$1.26m0.26%
$ 113.4k
Matthew Hill
CFO, Treasurer & Secretaryless than a yearUS$445.95k0.0072%
$ 3.2k
Moshe Citronowicz
Senior Vice President12.3yrsUS$538.31k1.32%
$ 575.2k
Todd Hornsby
Executive Vice President5.3yrsUS$746.27k0%
$ 0

5.8yrs

Average Tenure

55yo

Average Age

Experienced Management: APYX's management team is seasoned and experienced (5.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Charles Goodwin
President6.3yrsUS$1.26m0.26%
$ 113.4k
Andrew Makrides
Independent Chairman of the Board41.3yrsUS$124.06k1.8%
$ 786.7k
Michael Geraghty
Independent Director13.1yrsUS$114.06k0.079%
$ 34.7k
Lawrence Waldman
Lead Independent Director13.1yrsUS$162.56k0.12%
$ 54.1k
Brian Kinney
Member of Medical Advisory Board4.8yrsno datano data
Gregory Konesky
Member of Scientific Advisory Boardno dataUS$9.30kno data
Yuval Carmel
Member of Scientific Advisory Boardno datano datano data
John C. Andres
Independent Vice-Chairman of the Board9.8yrsUS$144.06k0%
$ 0
Minnie Baylor-Henry
Independent Director4.7yrsUS$116.56k0%
$ 0
Craig Swandal
Independent Director6.1yrsUS$106.56k0.17%
$ 75.8k
Dennis Chi
Member of Medical Advisory Board7.3yrsno datano data
Diane Duncan
Member of Medical Advisory Board5.9yrsno datano data

6.8yrs

Average Tenure

69yo

Average Age

Experienced Board: APYX's board of directors are considered experienced (6.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.